ELUNATE^®

 (fruquintinib) HUTCHMED

Composition:²

ELUNATE^® is an orally administered kinase inhibitor, available with 1 mg or 5 mg in capsule form.

Indication:²

ELUNATE^® is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.

References

1. ELREXFIO™. HIGHLIGHTS OF PRESCRIBING INFORMATIONUS 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761345s000lbl.pdf  2. FRUZAQLA™ (fruquintinib). HIGHLIGHTS OF PRESCRIBING INFORMATION. US 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217564s000lbl.pdf  3. MOUNJARO® (tirzepatide). HIGHLIGHTS OF PRESCRIBING INFORMATION. US 2023. https://pi.lilly.com/us/mounjaro-uspi.pdf?s=pi  4. TEZSPIRE® (tezepelumab-ekko) injection. HIGHLIGHTS OF PRESCRIBING INFORMATION. US 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761224s001lbl.pdf